Mahendra Andika Dwi, Hanifah Suci, Sari Chynthia Pradiftha
Department of Pharmacy, dr Soeradji Tirtonegoro General Hospital, Indonesian Islamic University, Klaten 57424, Indonesia; Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Islam Indonesia, Yogyakarta 55584, Indonesia.
Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Islam Indonesia, Yogyakarta 55584, Indonesia.
Farm Hosp. 2023 Jan-Feb;47(1):16-19. doi: 10.1016/j.farma.2022.11.007. Epub 2023 Jan 25.
The purpose of this study is to determine the most common incompatible and unknown compatibility drug combinations and determine the compatibility of each pair of drugs used in hospitals based on reference books and journals.
This is a prospective cross sectional study. All babies who were admitted to the Neonatal Intensive Care Units from May 1 to July 31 2021 were sample of the study. Patients who did not receive at least two drug coadministrated concurrently and who stayed less than 24 hours were excluded. Only drug-drug combinations were considered and the other non-drug administrations (electrolyte solutions, parenteral nutritions, and blood products) were excluded. Compatibility data were obtained from literature and online search engines [micromedex NeoFax Essentials 2020, UCL Hospitals Injectable Medicines Administration Guide: Pharmacy Department, 3rd Edition, Trissel Handbook on injectable drugs 15 edition, and published journals].
The most commonly prescribed drug combinations were ampicillin-gentamicin (31.72%), amikacin-ampicillin sulbactam (9.05%), amikacin-ampicillin sulbactam-aminophylline (3.08%). The most common drug incompatible combination was ampicillin - gentamicin (31.71%), for the most drug combinations whose compatibility unknown were amikacin-ampicillin sulbactam (9.05%).
The high prevalence of incompatible drugs and unknown compatibility was identified, so checking its compatibility can be carried out through a two-dimensional chart to minimize the incidence of incompatibilities.
本研究旨在确定最常见的不相容和未知相容性药物组合,并根据参考书和期刊确定医院使用的每对药物的相容性。
这是一项前瞻性横断面研究。2021年5月1日至7月31日入住新生儿重症监护病房的所有婴儿均为研究样本。未同时接受至少两种药物治疗且住院时间少于24小时的患者被排除。仅考虑药物与药物的组合,排除其他非药物给药(电解质溶液、肠外营养和血液制品)。相容性数据来自文献和在线搜索引擎[Micromedex NeoFax Essentials 2020、伦敦大学学院医院注射用药物管理指南:药剂科,第3版,Trissel注射用药物手册第15版,以及已发表的期刊]。
最常开具的药物组合是氨苄西林-庆大霉素(31.72%)、阿米卡星-氨苄西林舒巴坦(9.05%)、阿米卡星-氨苄西林舒巴坦-氨茶碱(3.08%)。最常见的药物不相容组合是氨苄西林-庆大霉素(31.71%),相容性未知的最常见药物组合是阿米卡星-氨苄西林舒巴坦(9.05%)。
已确定不相容药物和未知相容性的高发生率,因此可通过二维图表检查其相容性,以尽量减少不相容情况的发生。